CN115867280B - 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物 - Google Patents

用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物 Download PDF

Info

Publication number
CN115867280B
CN115867280B CN202180038082.7A CN202180038082A CN115867280B CN 115867280 B CN115867280 B CN 115867280B CN 202180038082 A CN202180038082 A CN 202180038082A CN 115867280 B CN115867280 B CN 115867280B
Authority
CN
China
Prior art keywords
amino
pyridinyl
triazolo
pyrimidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180038082.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115867280A (zh
Inventor
G·A·布朗
M·S·康格里夫
C·M·理查德森
R·保尔
S·P·安德鲁斯
J·S·马森
F·德弗洛里安
N·A·斯温
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexla Pharmaceuticals Uk Ltd
Original Assignee
Nexla Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexla Pharmaceuticals Uk Ltd filed Critical Nexla Pharmaceuticals Uk Ltd
Publication of CN115867280A publication Critical patent/CN115867280A/zh
Application granted granted Critical
Publication of CN115867280B publication Critical patent/CN115867280B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180038082.7A 2020-03-26 2021-03-25 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物 Active CN115867280B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994970P 2020-03-26 2020-03-26
US62/994970 2020-03-26
PCT/EP2021/057807 WO2021191379A1 (en) 2020-03-26 2021-03-25 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer

Publications (2)

Publication Number Publication Date
CN115867280A CN115867280A (zh) 2023-03-28
CN115867280B true CN115867280B (zh) 2025-05-27

Family

ID=75339741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038082.7A Active CN115867280B (zh) 2020-03-26 2021-03-25 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物

Country Status (8)

Country Link
US (1) US12528815B2 (https=)
EP (1) EP4126873A1 (https=)
JP (1) JP7774573B2 (https=)
KR (1) KR20230051118A (https=)
CN (1) CN115867280B (https=)
AU (1) AU2021243725A1 (https=)
CA (1) CA3177056A1 (https=)
WO (1) WO2021191379A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018166493A1 (zh) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
JP2011513417A (ja) * 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
AU2011306358B2 (en) 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018166493A1 (zh) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CA3177056A1 (en) 2021-09-30
US12528815B2 (en) 2026-01-20
JP7774573B2 (ja) 2025-11-21
JP2023519361A (ja) 2023-05-10
EP4126873A1 (en) 2023-02-08
KR20230051118A (ko) 2023-04-17
CN115867280A (zh) 2023-03-28
AU2021243725A1 (en) 2022-10-27
WO2021191379A1 (en) 2021-09-30
US20230146483A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
CN111936499B (zh) Mat2a的杂二环抑制剂和用于治疗癌症的方法
EP3647311B1 (en) Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
JP6430512B2 (ja) リジン特異的デメチラーゼ−１の阻害剤
CA2927252C (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CN104011052B (zh) 化合物
WO2015025026A1 (en) Alkynyl alcohols and methods of use
TW201127385A (en) N-containing heteroaryl derivatives as JAK3 kinase inhibitors
WO2025122619A1 (en) Kras g12c inhibitors
EP4327877A2 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN115867280B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
KR20140139023A (ko) 암을 치료하기 위한 6-(4-(1-아미노-3-하이드록시사이클로부틸)페닐)-5-페닐(퓨로, 싸이에노 또는 피롤로)[2,3-d]피리미딘-4-온 유도체
EP4455129A1 (en) Dna polymerase theta inhibitor and use thereof
CN115867282B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
JP7689923B2 (ja) チエノピリジノン化合物
WO2021156439A1 (en) Triazole compounds as adenosine receptor antagonists
CN117466897A (zh) 高选择性fgfr2抑制剂
CN115867550B (zh) 三唑酮化合物
TWI690528B (zh) 稠環雙環吡啶基衍生物
HK1225378A1 (en) Alkynyl alcohols and methods of use
HK1230202B (en) Inhibitors of lysine specific demethylase-1
HK1230202A1 (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Britain

Address after: Cambridge County, England

Applicant after: Nexla Pharmaceuticals UK Ltd.

Address before: Cambridge County, England

Applicant before: Heptares Therapeutics Ltd.

Country or region before: Britain

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant